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AbstrAct
Objective This study reviewed the news media coverage 
of statins, seeking to identify specific trends or differences 
in viewpoint between media outlets and examine common 
themes.
Design The study is a content analysis of the frequency 
and content of the reporting of statins in a selection of 
the British newsprint media. It involved an assessment 
of the number, timing and thematic content of articles 
followed by a discourse analysis examining the underlying 
narratives. The sample was the output of four UK 
newspapers, covering a broad-spectrum readership, over a 
six month timeframe 1 October 2013 to 31 March 2014.
results A total of 67 articles included reference to statins. 
The majority (39, 58%) were reporting or responding to 
publication of a clinical study. The ratio of negative to 
positive coverage was greater than 2:1 overall. In the more 
politically right-leaning newspapers, 67% of coverage 
was predominantly negative (30/45 articles); 32% in the 
more left-leaning papers (7/22 articles). Common themes 
were the perceived ‘medicalisation’ of the population; 
the balance between lifestyle modification and medical 
treatments in the primary prevention of heart disease; 
side effects and effectiveness of statins; pharmaceutical 
sponsorship and implications for the reliability of evidence; 
trust between the public and government, institutions, 
research organisations and the medical profession.
conclusions Newsprint media coverage of statins was 
substantially influenced by the publication of national 
guidance and by coverage in the medical journals 
of clinical studies and comment. Statins received a 
predominantly negative portrayal, notably in the more 
right-leaning press. There were shared themes: concern 
about the balance between medication and lifestyle 
change in the primary prevention of heart disease; the 
adverse effects of treatment; and a questioning of the 
reliability of evidence from research institutions, scientists 
and clinicians in the light of their potential allegiances and 
funding.
IntrODuctIOn
UK clinical guidelines recommend the use 
of lipid-lowering therapy for both secondary 
and primary prevention.1 2 This is based on 
published clinical trial evidence of effective-
ness, cost-effectiveness1 3–8 and the extent of 
side effects.7–9 There is debate in the clinical 
literature about the merits of the widespread 
and growing use of statins, questioning 
whether the ‘right’ patients are benefiting, 
whether the threshold for initiation of 
primary preventative treatment is too low and 
the reliability of the evidence underpinning 
the guidelines.10–16 The same issues are also 
covered in the lay media, where, however, the 
nature and extent of the debate are less well 
documented.
There is an interaction between the lay and 
clinical media, with the same commentators 
and topics or reported, or directly speaking, 
in both.17–20 Importantly, there is evidence 
that the lay media influences health-re-
lated perceptions and behaviours, including 
reporting of side effects, uptake of services 
and adherence to medication.21–26 The 
Chief Medical Officer for England called for 
a review into how the safety and efficacy of 
drugs was judged, prompted by concern about 
the representation of statins and other drugs 
‘in both the medical and general press’.27 A 
Danish study, using national and regional 
media coverage as a proxy for individual 
exposure, found that negative statin-related 
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Research
strengths and limitations of this study
 ► The use of media websites for data collection 
may have excluded some material which was 
only available in the print versions and conversely 
included some material not available in print.
 ► The pragmatic selection of the study timescale 
and media selection may have reduced the 
representativeness and therefore generalisability 
of the study; however, the sampling strategy was 
designed to ensure that the sources represented a 
reasonable range and diversity of the established 
newspaper media.
 ► There was a single researcher and not a research 
team, leading to a potential risk of bias or 
incompleteness in the identification and selection of 
articles, and no inter-rater reliability checking of the 
coding scheme, which may have an impact on the 
validity of the analyses.
 ► Blinding was not strictly possible, but articles were 
coded by a unique numerical identifier to reduce 
bias during the thematic analysis, and an inductive 
approach was applied to ensure that the themes 
were dictated by the evidence emerging from the 
texts and not imposed by the researcher.
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Table 1 Readership of selected newspapers 201340 41
Category Daily Mail Daily Mirror The Telegraph The Guardian
Circulation 1 863 000 1 058 500 555 600 204 400
Average age 58 Not given 61 44
Readership 65+ 45% 34% 46% 21%
Gender 51% female 54% male 52% male 52% male





North East and South East London
Predominant political 
stance**
Right Left Centre right Centre left
Market designation Tabloid Tabloid Broadsheet Broadsheet
* Social gradings A-E are based on 2011 UK census data. ABC1 represents higher & intermediate to clerical and junior occupations. 
** Political stance reflects party affiliation in the most recent general election. (Right: Conservative, UKIP; left: Labour, Green; Centre right: 
Conservative, Liberal Democrat; Centre left: Labour, Liberal Democrat.)
news stories were associated with both early statin discon-
tinuation and cardiovascular mortality.28
In the light of this relationship, it is relevant to examine 
the portrayal of statins in the media and the messages that 
are being predominantly received. This study investigates 
the nature of the representation of statins in the newsprint 
media, identifying the key themes, trends, characteristics 
and viewpoints.
MethOD
A descriptive and thematic analysis of the frequency of the 
coverage of statins in the UK newsprint media was under-
taken. Media were selected with the aim of obtaining 
broad-spectrum coverage reflecting a range of editorial 
leanings and readerships. An initial screening sample 
was undertaken in order to pilot the methodology and to 
consolidate the questions and sampling strategy for the 
main research.29 This identified what would be practical 
for one researcher to collect and enabled refinement of 
the range and type of outlets, the time period and the 
type of articles for inclusion in the main data collection. 
The sampling frame selected for the main study was the 
UK newsprint media. A purposive sampling strategy was 
followed, with newspapers selected on the basis that they 
were accessible, able to be searched and analysed by 
one researcher in the time available, and demographi-
cally, geographically and politically representative of a 
broad-spectrum readership. The selected newspapers 
were The Daily Mail, The Daily Mirror, The Telegraph 
and The Guardian (table 1). These are all national UK 
newspapers, recording high circulation.
Full texts of articles were searched by keyword and 
collected retrospectively from the websites of the selected 
media outlets over a continuous 6-month timeframe (1 
October 2013 to 31 March 2014). The main search term 
was ‘statin’ (‘statins’ did not retrieve all mentions.) A 
further search on ‘cholesterol’, ‘cardiovascular’ and 
‘heart disease’ was undertaken to confirm all relevant 
articles had been captured. All articles with any recorded 
mention of statins were screened. All types of article were 
included.
Articles were downloaded and printed in full. Each 
article was given a unique reference number, to blind 
the researcher to source during the analysis, and key 
descriptors were recorded. A thematic data analysis was 
then undertaken. A coding scheme provided a consistent 
framework for data collection and analysis and enabled 
independent third-party review. The exclusion criterion 
was peripheral mention of statins with no associated 
reporting or comment.
The analysis was in two parts. An initial descriptive 
analysis mapped the findings against the descriptive indi-
cators, including whether the coverage was judged to be 
predominantly positive or negative in terms of the argu-
ments, language and terminology.
Where the proportion of positive and negative 
comments appeared similar or where it was difficult to 
decide on the overall direction, a neutral assessment was 
given. A more detailed qualitative analysis then exam-
ined the nature of the discourses within the key themes, 
including viewpoints, assumptions and language. Outlets 
were then tracked back and identified in the results. A 
copy of the coding scheme is available as an online Supple-
mentary file 1.
There were no confidentiality issues associated with the 
study as all data sources were within the public domain. 
Ethics committee approval was not required.
results
Searches identified 67 articles during the time period. A 
timeline showing overage by outlet by week is shown in 
figure 1. There is considerable variation, with peaks in 
coverage weeks commencing 11 February and 18 March. 
The NICE revised draft guidelines were published on 12 
February,30 covered in 11 articles, prompting the earlier 
peak. A systematic review of the side effects of statins9 was 
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Figure 1 Coverage by outlet by week, October 2013–March 2014.
Table 2 Number, stance and theme of articles mentioning statins (1 October 2013 to 31 March 2014)
The Telegraph Daily Mail The Guardian Daily Mirror Total
Number of articles 25 20 11 11* 67
Frequency of article type
  Study report/response 10 (40.0%) 13 (65.0%) 6 (54.5%) 10 (90.9%) 39 (58.0%)
  Commentary 3 (12.0%) 1 (5.0%) 2 (18.2%) 0 (0.0%) 6 (9.0%)
  Q&A 2 (8.0%) 1 (5.0%) 0 (0.0%) 0 (0.0%) 3 (4.5%)
  Personal story 1 (4.0%) 1 (5.0%) 1 (9.1%) 0 (0.0%) 3 (4.5%)
  News report 1** (4.0%) 1** (5.0%) 0 (0.0%) 1** (9.1%) 3 (4.5%)
  Letters 4 (16.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (6.0%)
  Expert/’celebrity’ commentator 3 (12.0%) 2 (10.0%) 0 (0.0%) 0 (0.0%) 5 (7.5%)
  Other 1 (4.0%) 1 (5%) 2 (18.2%) 0 (0%) 4 (6.0%)
Statins main topic
  Main topic 18 (72.0%) 14 (70.0%) 10 (90.9%) 3 (27.3%) 45 (67.2%)
  Secondary topic 7 (28.0%) 6 (30.0%) 1 (9.1%) 8 (72.7%) 22 (32.8%)
Positive/negative
  Positive 2 (8.0%) 8 (40.0%) 3 (27.3%) 4 (36.4%) 17 (25.4%)
  Neutral 3 (12.0%) 2 (10.0%) 5 (45.4%) 3 (27.2%) 13 (19.4%)
  Negative 20 (80.0%) 10 (50.0%) 3 (27.3%) 4 (36.4%) 37 (55.2%)
*One article was excluded.
**Publication of NICE and US guidelines on the use of statins. 
widely reported a month later. In only five of the 26 weeks 
was there no story about statins.
In two-thirds of articles (table 2), statins were the main 
topic. The majority of articles (39, 58%) were reporting 
or responding to publication of a clinical study.
The ratio of negative to positive coverage was greater 
than 2:1 overall. The more right-leaning papers exhibited 
a ratio of 3:1 negative to positive articles, where the left 
leaning press had equal proportions of each. The Tele-
graph had the highest differential with a 10:1 ratio of 
negative to positive stories (figure 2). Articles on studies 
reporting collateral benefits (statins benefiting people 
with multiple sclerosis or dementia for example) were 
more likely to portray statins in a positive light.
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Figure 2 Positive and negative coverage.
thematic analysis
The themes with the highest number of mentions 
selected for detailed analysis were medicalisation versus 
lifestyle modification, the effectiveness of statins in the 
light of their side effects and trust of those advocating 
statin therapy.
Medicalisation versus lifestyle modification
The term ‘medicalisation’ is used by three of the four 
sampled media, both in quotes from contributors and by 
the article authors. In most cases, it is used to denote the 
introduction of drug treatment for use in an otherwise 
apparently healthy population. It is used with an exclu-
sively negative meaning:
'the ‘medicalisation’ of people who are not ill… 
turning five million middle-aged and predominantly 
healthy men and women into statin-popping 
patients' (Mail, 13 February 2014).
'It is a concern to have to mass medicalise the 
whole of the British public in this way’ (Telegraph, 
11 February 2014). Britain will be confirmed 'the 
statins capital of Europe' (Mail, 12 February 2014).
There is a language of passivity and control. People are 
‘medicalised’, ‘medicated’ or ‘put on statins’ (emphasis 
added).
The majority of articles appear supportive of prescribing 
statins for those with established heart disease. The 
controversy centres on what proportion of those with risk 
factors for cardiovascular disease should receive statins as 
a primary preventative measure:
‘there are people who may be overweight or have raised 
blood pressure. They probably don’t have symptoms. 
They are not ill’ (Guardian, 21 March 2014).
‘we’ll be medicalising many relatively healthy 
patients’ (Mail, 12 February 2014) (emphasis added)
The medical profession is seen to be focusing on the 
medical option in preference to promoting lifestyle 
change:
‘(It is) ‘simpler to reach for the pad and write 
out a prescription’ than to dole out lifestyle 
advice’ (National Obesity Forum quoted in Mail and 
Telegraph, 25 December 2013)
The public is also indicated to be at fault:
'There is a tendency… for patients (and doctors) to 
think that as long as they’re on statins, smoking or a 
poor diet doesn’t really matter';
'people will see them as a magic pill that allows 
them to tuck into three pizzas a night and umpteen 
hamburgers with impunity' (‘leading cardiologist’ 
quoted in Mail, 8 March 2014, 13 February 2014)
Lifestyle measures could actually be the preferable 
medicine:
‘Exercise can be just as efficient as drugs in treating 
heart disease’ (study report, Mirror, 2 October 2013)
‘eating an apple a day is as effective as tak-
ing statins’ (medical ‘campaigner’, Telegraph, 
2 March 2014)
effectiveness and side effects of treatment
The positioning of ‘expert’ opinion is important here. 
Who is most qualified to determine the impact of 
side effects: clinician, trialist or patient?
Evidence from published studies on the extent of 
side effects is reported:
‘the benefits of statins greatly exceed any side 
effects’ (Cholesterol trialists study report, Mail, 
12 February 2014).
This is directly challenged by individuals:
NICE 'will tell you that… one in 10 000 patients… will 
suffer severe muscular pain…. In contrast, reliable 
data from the real world… backed up by anecdotal 
evidence from my experience as a cardiac physician 
suggests that the real figure… is closer to one in five.' 
(cardiologist quoted in Mail, 13 February 2014)
'I know of only three people who have been on 
statins—I am one of them—and we all experienced 
debilitating muscle aches' (reader correspondence, 
Telegraph, 15 March 2014)
The ‘noise’ about side effects may produce the equiva-
lent of a ‘nocebo effect’:
‘If we tell people about side effects,… we induce 
these unpleasant symptoms,… inflicting harm on our 
patients’;
‘We… shouldn’t scare people into experiencing side 
effects… or into avoiding a medication which might 
help them’ (‘study author’, Guardian, 14 March 2014)
Statins are portrayed as either villain or hero:
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‘in years to come, statins could be seen as being as 
dangerous as thalidomide’ (reader correspondence, 
Mail, 14 November 2013)
‘Statins may reduce dementia by a third’ (study 
report, Telegraph, 30 December 2013)
Over the six month sample period, statins were asso-
ciated with potential beneficial effects on dementia, 
multiple sclerosis and erectile dysfunction.
trust
A related but distinct theme is trust. The reliability of 
studies or guidelines is traditionally linked to the weight 
of scientific evidence—usually randomised controlled 
trial evidence—underpinning them. However, there is an 
implied suspicion of the evidence based on the perceived 
trustworthiness of those producing or funding it. An 
interesting question emerges concerning which forms of 
evidence have the greater validity:
NICE recomendations are ‘based on solid evidence 
and the public should trust them’ (US study authors 
quoted in Mail, 13 November 2013)
‘The drug companies were saying this drug was 
the best thing since sliced bread’; ‘their findings 
are contradicted by independent surveys’ and they 
are ‘contrary to the experience of many Telegraph 
readers’ (response to draft NICE guidelines, 
Telegraph, 2 March 2014) 
‘trials run by the drug companies… are likely to be 
excessively favourable’ (Harvard clinician, Mail, 
24 December 2013) 
The confidentiality of some of the trial data leads to 
suspicion of what the data contain:
There is no reason 'to accept the analysis of the 
Oxford team who have seen the data at face value just 
because they are big and important and professors 
at Oxford University…. Either they don’t have 
a vast chunk of data or they do and they are not 
publishing it' (‘Scottish GP and author’, Guardian, 
21 March 2014)
Another dimension of trust is seen in the portrayal of 
organisations and institutions. Pharmaceutical compa-
nies are almost universally negatively portrayed. Some 
academic bodies are still largely to be trusted, for example
‘the respected Cochrane group’ (Guardian, 27 
October 2013)
but other organisations or individuals are contami-
nated by association: there are
‘arrangements between Big Pharma and 
academic institutions (and) vested interests in the 
research’ (Telegraph, 15 March 2014)
Political and administrative organisations receive a 
mixed portrayal:
'the government’s advice is based on a wealth of 
evidence. The BMJ article is based on opinion' (Public 
Health England director quoted in Guardian, 
23 October 2013)
‘how can we explain this big gap between… personal 
experience… of doctors and patients… and official 
bodies such as NICE?’ (Mail, 18 March 2014)
‘NICE seems to be siding firmly with the drug 
companies and relying on industry-sponsored 
statistics’ (Mail, 13 February 2014)
Family doctors receive consistently negative coverage. 
Medical authority is portrayed as siding with, or indirectly 
influenced by, the pharmaceutically sponsored institu-
tions. Doctors are accused of
‘inexcusable deviousness’
in their methods for fulfilling screening quotas and in 
disguising a prescription for statins as
‘lipid tablets’ (Telegraph, 16 February 2014)
There is a risk of:
‘more aggressive prescribing of (statin) medications 
by family doctors, whose pay is linked to take-
up of the pills among their patients’ (Telegraph, 
11 February 2014).
DIscussIOn
This study found that the newsprint media coverage 
of statins was substantially influenced by coverage in 
the medical journals of clinical studies, reports and 
comment. Statins received a predominantly negative 
portrayal overall, notably in the more right-leaning press. 
Specifically, there was considerable coverage of reported 
side effects; concern about the balance between medica-
tion and lifestyle changes in primary prevention; and a 
questioning of the reliability of evidence from research 
institutions, scientists and clinicians in the light of their 
potential allegiances and funding.
The findings are consistent with a number of earlier 
studies and also highlight some departures from previous 
research.
 ► The strongest criticism of statins and their effects in 
the media appears to reflect very closely the arguments 
presented in the medical journals over the same time 
period, although the weighting of the arguments may 
differ.10–12 In the popular press, there is no discerni-
ble difference in the reporting of what the scientific 
community might describe as important, high-quality 
studies compared with the reporting of small studies, 
or opinion, with high potential for bias. All views are 
portrayed with equal weight and seriousness. Other 
studies have identified greater selectivity in reporting 
in the popular compared with the specialist media, 
with a greater focus on more controversial topics.31
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 ► A notable trend identified in the media is for reports 
of new links between, for example, statins and demen-
tia, or statins and impotence, to be more uncritical 
than reports of the use of statins in preventing heart 
disease. With a new study, the results themselves are 
the story, whereas with the role of statins in the pre-
vention of heart disease, it is the debate and contro-
versy that is represented.
 ► In terms of the medication versus lifestyle debate, 
clinical studies disagree about the extent to which 
health-promoting behaviours are actually affected 
by long-term statin use.32–34 However, the newspaper 
coverage contained a largely judgemental vocabulary 
around the selection of a medical treatment pathway, 
suggesting that people who take tablets or doctors 
who prescribe them may be abdicating personal re-
sponsibility for health.
 ► The question of trust in institutions has also been 
highlighted in other research. Commentators have 
identified a tendency in the media to exaggerate and 
seek to mobilise opinion against a ‘supposed threat’ 
or conspiracy.35 In contrast, where previous research 
has placed clinicians—family doctors in particular—
high in the hierarchy of public trust,21 36 this study 
found no evidence of positive reporting of the med-
ical profession in relation to statins.
One question arising from this study is whether statins 
have a distinct status with respect to the debate. The 
polarisation of good drug/bad drug is not new. Other 
studies have reported a similarly dichotomised approach 
in relation to other medical treatments.22 37 There are 
parallels with the representation of the diagnosis and 
treatment of hypertension, another frequently invisible 
‘sickness’ addressed by long-term preventative medi-
cation.16 However, in the case of statins, the threshold 
for treatment appears increasingly to be driven by age 
rather than specific clinical indicators. (The QRisk cardi-
ovascular risk calculator is strongly influenced by age.) 
Everyone could eventually become a candidate for medi-
calisation, however healthy their lifestyle and however low 
their cholesterol ratio.
The study highlights a fundamental point concerning 
the significance of the portrayal of medical issues in 
the media: is it important that even someone reading 
across the whole range of newspaper coverage sampled 
for this study would receive a negative impression of the 
value of the scientific evidence and the benefit of statins, 
when current clinical guidance recommends their use? 
Coverage in the popular press highlights the confusing 
messages projected by science and research worldwide. 
There is no mediating discourse leading people through 
the pendulum findings of one study or learned commen-
tator after another. The ‘noise’ of the continuing debate 
may even be frightening people away from taking their 
prescribed medications and increasing cardiovascular 
mortality.17 28 This raises an ethical question around the 
desirability of presenting all viewpoints, however well or 
ill evidenced, at the risk of deterring people from acting 
responsibly with regard to their health. Other studies 
have suggested that there is scope for the scientific and 
medical worlds to articulate their messages more care-
fully for popular media consumption.26 37 38 Alternatively, 
the rawness and transparency of the debate may be a 
good thing. The ability to see and critique another scien-
tist’s work is valued by researchers, and it may also be of 
benefit to a non-medical audience to hear the challenge 
and defence of each viewpoint played out in the public 
arena. One response is for subject experts to provide an 
evidence-based commentary on scientific issues of public 
interest, along the lines of NHS Choices’ ‘Behind the 
Headlines’, developed by Sir Muir Gray because ‘In the 
same way that people need clean, clear water, they have a 
right to clean, clear knowledge’.39
This study adds insight into the portrayal of preventa-
tive medications and related clinical policy, in the media. 
There are potential implications for clinicians, study 
authors, policy makers and public health practitioners. 
By increasing awareness of the messages their patients, 
readers and the public are predominantly hearing in rela-
tion to their medications, it highlights the considerable 
scope for all health experts to promote a more media-
friendly, evidence-based narrative on health topics of 
public interest or concern.
Recommendations for further research include a 
comparison of a wider number of outlets and different 
areas of medicine over a longer period of time, a compar-
ison of the medical and popular media coverage in 
detail and further exploration of the impact of media 
coverage on reader health behaviours.
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